



GO 211.2-NDH #5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Thomas S. Parker, et al.  
Serial No. : 08/487,461  
Filed : June 7, 1995  
For : METHODS AND COMPOSITIONS USEFUL IN  
PROPHYLAXIS AND THERAPY OF ENDOTOXIN  
RELATED CONDITIONS

---

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

DECLARATION (37 C.F.R. §1.821(f))

Sir:

Norman D. Hanson hereby declares as follows:

1. I am the attorney in charge of the above identified application, and I am fully familiar with its contents.


2. I have compared the sequences presented in the specification of this application and the sequences submitted herewith in computer readable form and in paper copy. I attest that the information contained in these two sources is the same.

3. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the

like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

August 18, 1995

Date

  
Norman D. Hanson  
Reg. No. 30,946

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

**21  
14:15  
PAT. & TRADEMARK OFF.**  
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant must provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**Please return a copy of this notice with your response.**